Prostate cancer: Where are we and where are we going?

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 2-7

  Denmeade, S R ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; DISEASE COURSE; EARLY DIAGNOSIS; HEALTH ECONOMICS; HUMAN; MALE; MASS SCREENING; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGEN ANTAGONISTS; HEALTH CARE COSTS; HUMANS; MALE; MASS SCREENING; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 0031403739     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00794.x     Document Type: Article

References (43)

1. Isaacs JT. Role of androgens in prostatic cancer. Vit Hormones 1994; 49: 433-502
2. Parker SL. Tong T. Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996: 65: 5-27
3. Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health 1989; 79: 1490-3
4. Carter HB, Coffey DS. Prostate cancer: The magnitude of the problem in the United States. In Coffey DS, Resnick MI, Dorr FA, Karr JP, eds, A Multidisciplinary Analysis of Controversies in the Management of Prostate Cancer. New York: Plenum Press, 1988: 1-9
5. Johannson JE, Adami HO, Anderson SO, Bergstom R, Krusemo UB, Kraaz W. Natural history of localized prostatic cancer. Lancet 1980; 1: 799-803
6. Walsh PC, Jewett HJ. Radical surgery for prostatic cancer. Cancer 1980; 45: 1906-11
7. Raghaven D. Non-hormone chemotherapy for prostate cancer: Principles of treatment and application to the testing of new drugs. Semin Oncol 1988; 15: 371-89
8. Crawford ED, Eisenberger MA, McLeod DC et al. A controlled randomised trial of leuprolide with and without flutamide in prostatic cancer. New Engl J Med 1989; 321: 419-24
9. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-8
10. Gleason DF, Mellinger GT and the Veterans Administrative Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64
11. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990; 143: 742-6
12. Thompson IM, Chodak GW. The natural history of adenocarcinoma of the prostate. J Cell Biochem 1992; 16H: 20-5
13. Vallancien G, Prapotnich D, Veillon B, Brisset JM, AndreBougaran J. Systematic prostatic biopsies in 100 men with no suspicion of cancer on digital rectal examination. J Urol 1991; 146: 1308-12
14. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992: 23: 211-22
15. Isaacs JT. Relationship between tumor size and curability of prostatic cancer by combined chemohormonal therapy in rats. Cancer Res 1989; 49: 6290-4
16. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffee DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 1994; 25: 249-65
17. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostatic cancer cells containing mutant p53 alleles. Cancer Res 1991; 51: 4716-20
18. Navone N, Troncoso P. Pisters LL, Palmer JL, vonEshenbach AC. Sand Conte CJ. P53 protein accumulation and gene mutation in the progession of human prostate carcinoma. J Nat Cancer Jnst 1993; 85: 1657-69
19. Ichikawa T, Isaacs JT. Takeichi M, Debruyne FMJ. Schalken JA. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992; 52: 2916-22
20. Umbas R, Schalken JA, Aalders TW et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostatic cancer. Cancer Res 1992; 52: 5104-9
21. Dong J-T, Lamb PW. Rinker-Schaeffer CW et al. KAI-1, a metastasis suppressor gene for prostate cancer on human chromosome llpll.2. Science 1995; 268: 884-6
22. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of proto-oncogene bcl-2 in the prostate and its association with emergency of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4
23. Colombel M, Symmons F, Gil S et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormonerefractory human prostate cancers. Am J Pathol 1993; 143: 390-400
24. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996; 2: 389-98
25. Partin AW, Isaacs JT, Treiger B, Coffey DS. Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with v-Harvey-ras oncogene. Cancer Res 1988; 48: 2043-6
26. Weidner N, Carrol PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9
27. Bigler SA, Brawer MK, Deering RE. Comparison of microscopic vascularity in benign and malignant prostatic tissue. Hum Pathol 1993; 24: 220-6
28. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996: 28: 251-65
29. Furuya Y, Lin XS, Walsh JC, Nelson WG, Isaacs JT. Androgen ablation-induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 1995; 136: 1898-906
30. Berges RR, Vukanovic J, Epstein JI et al. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-80
31. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994; 24: 244-51
32. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31
33. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, HartleyAsp B, Isaacs JT. Antiangiogenic effects of the quinoline3-carboxamide linomide. Cancer Res 1993; 53: 1833-7
34. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55: 1499-504
35. Vukanovic J. Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. Cancer Res 1995; 55: 3517-20
36. Vukanovic J, Hartley-Asp B, Isaacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate 1995; 26: 235-46
37. Martikainen P. Kyprianou N, Tucker RW, Isaacs JT. Programmed death of non-proliferating androgen independent prostatic cancer cells. Cancer Res 1991; 51: 4693-700
38. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994; 54: 6167-75
39. Furuya Y, Isaacs JT. Proliferation dependent vs. independent programmed cell death of prostatic cancer cells involving distinct gene regulation. Prostate 1994; 25: 301-9
40. Christensson A, Laurell CB, Lilja H. Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur ] Biochem 1990; 194: 755-65
41. 1-antichymotrypsin. Clin Chem 1991; 37: 1618-25
42. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominate protein in human semen. J Biol Chem 1989; 264: 1894-900
43. 2+ ATPase. FEES Letters 1993; 335: 345-8